Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PFE Stock Forecast 2025-2026
$23.04
Current Price
$130.00B
Market Cap
Buy 9
Hold 15
Sell 1
Wall St Analyst Ratings
Distance to PFE Price Targets
+82.3%
To High Target of $42.00
+21.5%
To Median Target of $28.00
-0.2%
To Low Target of $23.00
PFE Price Momentum
+0.9%
1 Week Change
+2.9%
1 Month Change
-19.7%
1 Year Change
-13.2%
Year-to-Date Change
-26.9%
From 52W High of $31.54
+10.1%
From 52W Low of $20.92
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Pfizer (PFE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PFE and similar high-potential opportunities.
Latest PFE Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, PFE has a neutral consensus with a median price target of $28.00 (ranging from $23.00 to $42.00). The overall analyst rating is Buy (7.1/10). Currently trading at $23.04, the median forecast implies a 21.5% upside. This outlook is supported by 9 Buy, 15 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Robyn Karnauskas at Truist Securities, projecting a 82.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PFE Analyst Ratings
9
Buy
15
Hold
1
Sell
PFE Price Target Range
Low
$23.00
Average
$28.00
High
$42.00
Current: $23.04
Latest PFE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PFE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2025 | UBS | Trung Huynh | Neutral | Maintains | $25.00 |
| Apr 22, 2025 | Cantor Fitzgerald | Carter Gould | Neutral | Initiates | $24.00 |
| Apr 8, 2025 | UBS | Trung Huynh | Neutral | Maintains | $24.00 |
| Apr 8, 2025 | Goldman Sachs | Asad Haider | Neutral | Downgrade | $25.00 |
| Mar 18, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $0.00 |
| Mar 12, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $0.00 |
| Feb 10, 2025 | Guggenheim | Vamil Divan | Buy | Reiterates | $33.00 |
| Feb 5, 2025 | UBS | Colin Bristow | Neutral | Maintains | $28.00 |
| Jan 28, 2025 | Citigroup | Andrew Baum | Neutral | Maintains | $29.00 |
| Jan 8, 2025 | UBS | Colin Bristow | Neutral | Maintains | $29.00 |
| Dec 18, 2024 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $32.00 |
| Dec 11, 2024 | Guggenheim | Vamil Divan | Buy | Maintains | $33.00 |
| Dec 10, 2024 | B of A Securities | Tim Anderson | Neutral | Reinstates | $29.00 |
| Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Underperform | Initiates | $25.00 |
| Oct 30, 2024 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
| Oct 25, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $45.00 |
| Oct 23, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $45.00 |
| Oct 17, 2024 | Bernstein | Courtney Breen | Market Perform | Initiates | $32.00 |
| Oct 11, 2024 | Morgan Stanley | Equal-Weight | Maintains | $0.00 | |
| Oct 3, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $45.00 |
Pfizer Inc. (PFE) Competitors
The following stocks are similar to Pfizer based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pfizer Inc. (PFE) Financial Data
Pfizer Inc. has a market capitalization of $130.00B with a P/E ratio of 16.6x. The company generates $62.46B in trailing twelve-month revenue with a 12.6% profit margin.
Revenue growth is -7.8% quarter-over-quarter, while maintaining an operating margin of +35.2% and return on equity of +8.6%.
Valuation Metrics
Market Cap
$130.00B
Enterprise Value
$176.37B
P/E Ratio
16.6x
PEG Ratio
7.8x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
-7.8%
Gross Margin
+79.3%
Operating Margin
+35.2%
Net Margin
+12.6%
EPS Growth
-4.8%
Financial Health
Cash/Price Ratio
+13.2%
Current Ratio
1.3x
Debt/Equity
68.8x
ROE
+8.6%
ROA
+4.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Pfizer Inc. (PFE) Business Model
About Pfizer Inc.
What They Do
Develops innovative medicines and vaccines.
Business Model
Pfizer generates revenue through the research, development, and manufacturing of healthcare products, including prescription medicines and vaccines. The company focuses on various therapeutic areas and maintains a strong pipeline of products in clinical development, which helps sustain its profitability and market presence.
Additional Information
Headquartered in New York City, Pfizer is a significant player in the global pharmaceutical landscape, contributing to public health with breakthroughs in treatments for critical diseases. Its collaborations with scientific communities and healthcare systems reinforce its role in addressing urgent medical needs and influencing market trends.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
81,000
CEO
Dr. Albert Bourla D.V.M., Ph.D.
Country
United States
IPO Year
1972
Website
www.pfizer.comPfizer Inc. (PFE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
The Zacks Analyst Blog Highlights Pfizer, Coca-Cola and The Walt Disney
Pfizer, Coca-Cola and The Walt Disney are part of the Zacks top Analyst Blog.
May 21, 2025
By Zacks Equity Research
Press Releases
MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug
The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.
May 20, 2025
By Zacks Equity Research
Analyst Blog
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential
Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.
May 20, 2025
By Nalak Das
Analyst Blog
Latest News
Quick Summary
CNBC's Angelica Peebles reported on the latest news during a segment on 'Squawk Box.' No specific financial details were mentioned in the excerpt.
Why It Matters
The report may influence market sentiment and impact stock prices, as it could cover significant economic developments or company news affecting investment decisions.
Source: CNBC Television
Market Sentiment:
Positive
Quick Summary
Pfizer (PFE) has entered into a new agreement with Chinese firm 3SBio to develop and market a cancer drug currently in development.
Why It Matters
Pfizer's agreement with 3SBio may enhance its oncology portfolio, potentially leading to increased revenues and market share in a lucrative sector, impacting stock performance positively.
Source: Investopedia
Market Sentiment:
Positive
Pfizer Pacing for 4th Day of Gains
2 days ago
Quick Summary
Pfizer has finalized a deal for a new cancer drug, contributing to its stock's fourth consecutive day of gains.
Why It Matters
Pfizer's new cancer drug deal can boost future revenues and market confidence, driving stock momentum and attracting investor interest.
Source: CNBC Television
Market Sentiment:
Positive
Quick Summary
Pfizer has signed a licensing agreement with 3SBio worth up to $6 billion to develop the experimental cancer drug SSGJ-707, currently in trials for lung, colorectal, and gynecological cancers.
Why It Matters
Pfizer's $6 billion deal with 3SBio enhances its oncology pipeline, potentially driving future revenue growth and market share in cancer treatments, impacting stock performance positively.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Pfizer has signed a licensing agreement with China-based 3SBio for an experimental drug, indicating a strategic partnership in pharmaceutical development.
Why It Matters
Pfizer's licensing deal with 3SBio could enhance revenue streams through market expansion, boost innovative drug development, and indicate strong international collaboration, impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PFE has acquired global rights, excluding China, to SSGJ-707 from 3SBio for an upfront payment of $1.25 billion.
Why It Matters
PFE's $1.25 billion deal for SSGJ-707 expands its pipeline and enhances growth potential, signaling confidence in future revenue streams and strategic positioning in biotech.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About PFE Stock
What is Pfizer Inc.'s (PFE) stock forecast for 2025?
Based on our analysis of 33 Wall Street analysts, Pfizer Inc. (PFE) has a median price target of $28.00. The highest price target is $42.00 and the lowest is $23.00.
Is PFE stock a good investment in 2025?
According to current analyst ratings, PFE has 9 Buy ratings, 15 Hold ratings, and 1 Sell ratings. The stock is currently trading at $23.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PFE stock?
Wall Street analysts predict PFE stock could reach $28.00 in the next 12 months. This represents a 21.5% increase from the current price of $23.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pfizer Inc.'s business model?
Pfizer generates revenue through the research, development, and manufacturing of healthcare products, including prescription medicines and vaccines. The company focuses on various therapeutic areas and maintains a strong pipeline of products in clinical development, which helps sustain its profitability and market presence.
What is the highest forecasted price for PFE Pfizer Inc.?
The highest price target for PFE is $42.00 from Robyn Karnauskas at Truist Securities, which represents a 82.3% increase from the current price of $23.04.
What is the lowest forecasted price for PFE Pfizer Inc.?
Price targets from Wall Street analysts for PFE are not currently available. The stock is trading at $23.04.
What is the overall PFE consensus from analysts for Pfizer Inc.?
The overall analyst consensus for PFE is neutral. Out of 33 Wall Street analysts, 9 rate it as Buy, 15 as Hold, and 1 as Sell, with a median price target of $28.00.
How accurate are PFE stock price projections?
Stock price projections, including those for Pfizer Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 7:37 PM UTC